<br>        Inclusion Criteria:<br><br>          -  Confirmed new diagnosis of Philadelphia chromosome or BCR-ABL positive acute<br>             lymphoblastic leukemia<br><br>          -  Male or female patients aged 18-55 years<br><br>          -  Not previously treated except for prephase (corticosteroids, cyclophosphamide, single<br>             dose VCR will be permitted) therapy during establishment of the diagnosis<br><br>          -  Signed written inform consent, willingness and ability to comply with all study<br>             procedures<br><br>          -  Molecular detection of BCR-ABL transcripts<br><br>          -  Willingness of women of child-bearing potential (WOCBP) and male subjects whose<br>             sexual partners are WOCBP, to use an effective form of contraception (pearl index <<br>             1%), such as complete sexual abstinence, combined oral contraceptive, hormone IUCD,<br>             vaginal hormone ring, transdermal contraceptive patch, contraceptive implant or depot<br>             contraceptive injection in combination with a second method of contraception like a<br>             condom or a cervical cap / diaphragm with spermicide or surgical sterilisation<br>             (vasectomy) in male patients or male partners during the study and at least 6 months<br>             thereafter. WOCBP are defined as sexually mature women who have not undergone a<br>             hysterectomy or surgical sterilization or who have not been naturally postmenopausal<br>             for at least 12 consecutive months (i.e., who has had menses any time in the<br>             preceding 12 consecutive months).<br><br>          -  Negative pregnancy test for women of child-bearing potential.<br><br>        Exclusion Criteria:<br><br>          -  Patients with ECOG status > 2<br><br>          -  Patients with QTcF > 470 ms<br><br>          -  Cardiac insufficiency NYHA grade III/IV, LEVF < 50%, myocardial infarction within the<br>             past 6 months prior to study<br><br>          -  Active secondary malignancy requiring treatment<br><br>          -  Patients with active, uncontrolled bacterial, viral or fungal infection<br><br>          -  Known infection with HIV, Hepatitis B (except post vaccinal profile) or C<br><br>          -  Inadequate hepatic functions defined as ASAT or ALAT > 2,5 times the institutional<br>             upper limit of normal and total bilirubin > 2 fold the institutional upper limit<br>             unless considered to be due to organ involvement by the leukemia<br><br>          -  Concurrent severe diseases which exclude the administration of therapy<br><br>          -  Expected non-compliance or inability to understand informed consent<br><br>          -  Female patients who are pregnant or breast feeding<br><br>          -  Treatment with other investigational antileukemic agents after informed consent.<br>